Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
10.73
-0.37 (-3.33%)
At close: Jul 24, 2026, 4:00 PM EDT
11.17
+0.44 (4.10%)
Pre-market: Jul 27, 2026, 4:41 AM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 377 employees as of December 31, 2025. The number of employees decreased by 26 or -6.45% compared to the previous year.
Employees
377
Change (1Y)
-26
Growth (1Y)
-6.45%
Revenue / Employee
$175,310
Profits / Employee
-$1,046,674
Market Cap
1.50B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 377 | -26 | -6.45% |
| Dec 31, 2024 | 403 | -123 | -23.38% |
| Dec 31, 2023 | 526 | -72 | -12.04% |
| Dec 31, 2022 | 598 | 113 | 23.30% |
| Dec 31, 2021 | 485 | 173 | 55.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| AbCellera Biologics | 562 |
| Vir Biotechnology | 367 |
| Xencor | 260 |
| Innoviva | 159 |
| Maze Therapeutics | 141 |
| Septerna | 130 |
| MoonLake Immunotherapeutics | 130 |
NTLA News
- 11 days ago - Intellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research - TheFly
- 16 days ago - Intellia Therapeutics price target raised to $17 from $12 at Wedbush - TheFly
- 20 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Intellia Therapeutics rises 12.9% - TheFly
- 5 weeks ago - Intellia Therapeutics rises 10.7% - TheFly
- 6 weeks ago - Intellia Therapeutics presents additional results from Phase 3 HAELO trial - TheFly
- 6 weeks ago - Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - GlobeNewsWire
- 6 weeks ago - Intellia Therapeutics Transcript: AGM 2026 - Transcripts